Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tamoxifen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 8/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tamoxifen SCHEMBL5328781 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1TP53KMT2A | |
| Tamoxifen SCHEMBL6365 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1TP53KMT2A | |
| Tamoxifen SCHEMBL10336277 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1TP53KMT2A | |
| Tamoxifen SCHEMBL178086 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1TP53KMT2A | |
| Tamoxifen SCHEMBL26077 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1TP53KMT2A | |
| Tamoxifen SCHEMBL17164701 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1TP53KMT2A | |
| Tamoxifen SCHEMBL7744729 | 0.98 | ESR1 (0.96) | ESR1ESR2MEN1TP53KMT2A | |
| Tamoxifen SCHEMBL5322913 | 0.97 | ESR1 (0.94) | ESR1ESR2MEN1TP53KMT2A | |
| SCHEMBL4104443 | 0.94 | ESR1 (0.89) | ESR1ESR2MEN1TP53KMT2A | |
| Toremifene SCHEMBL21464516 | 0.93 | ESR1 (0.87) | ESR1ESR2MEN1TP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1164197-B1 | A method for mass production of taxol by elicitations | SAMYANG GENEX CO LTD (KR) | 2006-03-08 | — | — | EP | claimed |
| EP-0769064-B1 | A METHOD FOR MASS PRODUCTION OF TAXOL BY SEMI-CONTINUOUS CULTURE | SAMYANG GENEX CO LTD (KR) | 2002-08-28 | — | — | EP | claimed |
| EP-3621633-A2 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | Aileron Therapeutics, Inc. (US) | 2020-03-18 | — | — | EP | disclosed |
| US-20200040102-A1 | ANTI-C10ORF54 ANTIBODIES AND USES THEREOF | PIERRE FABRE MEDICAMENT (FR) | 2020-02-06 | — | — | US | disclosed |
| CN-110167527-A | Use of coconut water as extraction solvent | 巴斯夫美容护理法国公司 | 2019-08-23 | — | — | CN | disclosed |
| EP-3095462-B1 | THERAPEUTIC PHARMACEUTICAL COMPOSITION EMPLOYING ANTI-SLC6A6 ANTIBODY | ORDER MADE MEDICAL RES INC (JP) | 2019-08-14 | — | — | EP | disclosed |
| US-20190127461-A1 | CANCER TREATMENT PHARMACEUTICAL COMPOSITION USING ANTI-MCT5 ANTIBODY | ORDER-MADE MEDICAL RESEARCH INC. (JP) | 2019-05-02 | — | — | US | disclosed |
| EP-3441465-A1 | CANCER TREATMENT PHARMACEUTICAL COMPOSITION USING ANTI-MCT5 ANTIBODY | Order-Made Medical Research Inc. (JP) | 2019-02-13 | — | — | EP | disclosed |
| WO-2018208954-A2 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. (US) | 2018-11-15 | — | — | WO | disclosed |
| US-10100123-B2 | Anti-C10orf54 antibodies and uses thereof | PIERRE FABRE MEDICAMENT (FR) | 2018-10-16 | — | — | US | disclosed |
| EP-3344275-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | Aileron Therapeutics, Inc. (US) | 2018-07-11 | — | — | EP | disclosed |
| US-7537762-B2 | Human monoclonal antibodies to activin receptor-like kinase-1 | AMGEN FREMONT, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| CN-1957944-A | Application of yew amylose in pharmacy | TAIKANG CHINESE YEW BIOENGINEE (CN) | 2007-05-09 | — | — | CN | disclosed |
| CN-1141968-C | Taxus chinensis health-care composite for reducing blood sugar | 邹跃翔 | 2004-03-17 | — | — | CN | disclosed |
| CN-1411832-A | Taxus chinensis health-care composition for reducing blood pressure | ZOU YUEXIANG (CN) | 2003-04-23 | — | — | CN | disclosed |
| CN-1348797-A | Healthy taxad composite for treating menalgia | ZOU YUEXIANG (CN) | 2002-05-15 | — | — | CN | disclosed |
| CN-1347727-A | Pharyngitis treating health taxad composition | ZOU YUEXIANG (CN) | 2002-05-08 | — | — | CN | disclosed |
| CN-1346659-A | Anticancer health-care Chinese yew composition | ZOU YUEXIANG (CN) | 2002-05-01 | — | — | CN | disclosed |
| CN-1344553-A | Cancer preventing combined health yew decoction and its making process | ZOU YUEXIANG (CN) | 2002-04-17 | — | — | CN | disclosed |
| CN-1341442-A | Taxus chinensis health-care composite for reducing blood sugar | ZOU YUEXIANG (CN) | 2002-03-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200040102-A1 | ANTI-C10ORF54 ANTIBODIES AND USES THEREOF | CD2BP2, DCLRE1B, CLTB | ESR1 4444/4885ESR2 3469/4885MEN1 3004/4885 |
| US-10100123-B2 | Anti-C10orf54 antibodies and uses thereof | CD2BP2, DCLRE1B, CLTB | ESR1 4444/4885ESR2 3469/4885MEN1 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.